
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis is in a strong financial position, with an estimated firm value of ~$14.1B and ~$1.6B in cash and equivalents. The company is seeing continued growth acceleration in their Cabometyx franchise, with a leading market share in RCC and 2L+ NET. While there are risks, such as potential generic erosion and the need to generate favorable data from ongoing clinical programs, the company's momentum and promising pipeline make it a compelling investment opportunity.
Bears say
Exelixis is facing increasing competition and visibility into near-and long-term growth trends is limited, while a strong balance sheet and profitability may differentiate it from peers, questions remain about the company's ability to maintain exclusivity for their flagship drug, Cabometyx, beyond FY26. Upcoming catalysts such as the initiation of the STELLAR-201 trial and potential FDA approval for zanzalintinib may provide some market sentiment, but overall, the commercial future of the company's pipeline is uncertain.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares